BlackRock’s scPharmaceuticals SCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-2,380,477
| Closed | -$13.5M | – | 5622 |
|
|
2025
Q3 | $13.5M | Buy |
2,380,477
+169,161
| +8% | +$866K | ﹤0.01% | 3292 |
|
|
2025
Q2 | $8.43M | Sell |
2,211,316
-145,496
| -6% | -$452K | ﹤0.01% | 3495 |
|
|
2025
Q1 | $6.2M | Buy |
2,356,812
+73,639
| +3% | +$240K | ﹤0.01% | 3553 |
|
|
2024
Q4 | $8.08M | Buy |
2,283,173
+429,424
| +23% | +$1.64M | ﹤0.01% | 3532 |
|
|
2024
Q3 | $8.45M | Buy |
1,853,749
+85,080
| +5% | +$412K | ﹤0.01% | 3492 |
|
|
2024
Q2 | $7.69M | Sell |
1,768,669
-32,941
| -2% | -$145K | ﹤0.01% | 3520 |
|
|
2024
Q1 | $9.04M | Sell |
1,801,610
-61,829
| -3% | -$346K | ﹤0.01% | 3395 |
|
|
2023
Q4 | $11.7M | Buy |
1,863,439
+134,319
| +8% | +$769K | ﹤0.01% | 3318 |
|
|
2023
Q3 | $12.3M | Sell |
1,729,120
-308
| -0% | -$2.43K | ﹤0.01% | 3211 |
|
|
2023
Q2 | $17.6M | Buy |
1,729,428
+1,617,539
| +1,446% | +$16.9M | ﹤0.01% | 3117 |
|
|
2023
Q1 | $1.01M | Buy |
111,889
+47,727
| +74% | +$350K | ﹤0.01% | 4331 |
|
|
2022
Q4 | $460K | Sell |
64,162
-640
| -1% | -$3.91K | ﹤0.01% | 4626 |
|
|
2022
Q3 | $422K | Buy |
64,802
+14
| +0% | +$75 | ﹤0.01% | 4774 |
|
|
2022
Q2 | $313K | Buy |
64,788
+6,905
| +12% | +$34.2K | ﹤0.01% | 4911 |
|
|
2022
Q1 | $329K | Sell |
57,883
-1,602
| -3% | -$7.87K | ﹤0.01% | 4988 |
|
|
2021
Q4 | $298K | Buy |
59,485
+1,380
| +2% | +$7.59K | ﹤0.01% | 5010 |
|
|
2021
Q3 | $387K | Sell |
58,105
-4,092
| -7% | -$24.5K | ﹤0.01% | 4829 |
|
|
2021
Q2 | $380K | Sell |
62,197
-266,972
| -81% | -$1.61M | ﹤0.01% | 4759 |
|
|
2021
Q1 | $2.19M | Buy |
329,169
+6,866
| +2% | +$47.1K | ﹤0.01% | 4262 |
|
|
2020
Q4 | $1.71M | Buy |
322,303
+62,827
| +24% | +$492K | ﹤0.01% | 4085 |
|
|
2020
Q3 | $1.93M | Buy |
259,476
+1,116
| +0.4% | +$8.72K | ﹤0.01% | 3911 |
|
|
2020
Q2 | $1.9M | Buy |
258,360
+238,148
| +1,178% | +$2.09M | ﹤0.01% | 3834 |
|
|
2020
Q1 | $150K | Buy |
20,212
+316
| +2% | +$2.29K | ﹤0.01% | 4280 |
|
|
2019
Q4 | $112K | Buy |
19,896
+2,306
| +13% | +$11.8K | ﹤0.01% | 4426 |
|
|
2019
Q3 | $104K | Sell |
17,590
-990
| -5% | -$5.58K | ﹤0.01% | 4436 |
|
|
2019
Q2 | $60K | Sell |
18,580
-326,307
| -95% | -$1.07M | ﹤0.01% | 4559 |
|
|
2019
Q1 | $1.03M | Sell |
344,887
-13,356
| -4% | -$45.9K | ﹤0.01% | 3900 |
|
|
2018
Q4 | $1.35M | Buy |
358,243
+7,094
| +2% | +$33.3K | ﹤0.01% | 3791 |
|
|
2018
Q3 | $2.06M | Buy |
351,149
+3,063
| +0.9% | +$15.6K | ﹤0.01% | 3764 |
|
|
2018
Q2 | $1.97M | Buy |
348,086
+59,617
| +21% | +$613K | ﹤0.01% | 3744 |
|
|
2018
Q1 | $3.58M | Buy |
288,469
+287,105
| +21,049% | +$3.86M | ﹤0.01% | 3523 |
|
|
2017
Q4 | $16K | Buy |
+1,364
| New | +$19.3K | ﹤0.01% | 4595 |
|
BlackRock's SCPH Position: Q4 2025 in Review
BlackRock sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 2,380,477 shares — an estimated $13.5M sold.
BlackRock first reported a position in SCPH in Q4 2017 and held it in 32 quarters. The position peaked at $17.6M in Q2 2023. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.
- BlackRock reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
- BlackRock sold 2,380,477 scPharmaceuticals shares in Q4 2025, an estimated $13.5M.
- BlackRock first reported a position in scPharmaceuticals in Q4 2017 and held it in 32 quarters.
- BlackRock's scPharmaceuticals position peaked at $17.6M in Q2 2023.
- 0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.
Based on BlackRock's 13F filing for Q4 2025, filed 12 Feb 2026.